Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans

Lei Li, Li Che, Kevin M. Tharp, Hyo‐Min Park, Maria G. Pilo, Dan Cao, Antonio Cigliano, Gavinella Latte, Zhong Xu, Silvia Ribback, Frank Dombrowski, Matthias Evert, Gregory J. Gores, Andreas Stahl, Diego F. Calvisi, Xin Chen – 22 February 2016 – Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most prevalent types of primary liver cancer. These malignancies have limited treatment options, resulting in poor patient outcomes. Metabolism reprogramming, including increased de novo lipogenesis, is one of the hallmarks of cancer.

MAF1 suppresses AKT‐mTOR signaling and liver cancer through activation of PTEN transcription

Yue Li, Chi Kwan Tsang, Suihai Wang, Xiao‐Xing Li, Yang Yang, Liwu Fu, Wenlin Huang, Ming Li, Hui‐Yun Wang, X.F. Steven Zheng – 22 February 2016 – The phosphatidylinositol 3‐kinase/phosphatidylinositol 3,4,5‐trisphosphate 3‐phosphatase/protein kinase B/mammalian target of rapamycin (PI3K‐PTEN‐AKT‐mTOR) pathway is a central controller of cell growth and a key driver for human cancer. MAF1 is an mTOR downstream effector and transcriptional repressor of ribosomal and transfer RNA genes.

Sox9 regulates self‐renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma

Chungang Liu, Limei Liu, Xuejiao Chen, Jiamin Cheng, Heng Zhang, Junjie Shen, Juanjuan Shan, Yanmin Xu, Zhi Yang, Maode Lai, Cheng Qian – 22 February 2016 – Hepatocellular carcinoma (HCC) is a highly aggressive liver tumor containing cancer stem cells (CSCs) that participate in tumor propagation, resistance to conventional therapy, and promotion of tumor recurrence, causing poor patient outcomes. The protein SRY (sex determining region Y)‐box 9 (Sox9) is a transcription factor expressed in some solid tumors, including HCC.

Subscribe to